<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414934</url>
  </required_header>
  <id_info>
    <org_study_id>941220</org_study_id>
    <nct_id>NCT00414934</nct_id>
  </id_info>
  <brief_title>18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer.</brief_title>
  <official_title>The Effectiveness of Whole-body 18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer: A Comparison Study With 99mTc-MDP Bone Scintigraphy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      18F ion is a positron emitting bone radiopharmaceuticals. The skeletal uptake of 18F relies
      on the exchange of hydroxyl ions in the hydroxyapatit crystal which is an indicator of bone
      metabolic activity (8). It has good soft tissue clearance and high affinity of to the bone
      matrix. It is able to perform a highly sensitive whole-body screening for bone metastases
      using a high resolution PET scanner. Therefore, we conduct a prospective study to evaluate
      the accuracy and clinical value of 18F PET in staging bone metastases by

        1. Comparing the sensitivity of 18F-NaF PET with that of 99mTc-MDP scintigraphy;

        2. Determining the clinical impact of PET results on subsequent patient management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Skeletal metastases are the most common cause of morbidity and mortality in patients with
      malignancy, especially in patients with breast cancer, lung cancer, prostate cancer and head
      &amp; neck cancer. In patients with lung cancer, bone metastases are present in 20-30% of patient
      at initial diagnosis (1-2). Accuracy staging bone metastases can lead to modification of
      following treatment and evaluation of prognosis.

      The planar whole-body 99mTc-methylene diphosphonate (MDP) radionuclide bone scintigraphy is
      the most widely used technique in detecting metastatic bone lesions at present. Abnormal
      tracer accumulation may occur at any skeletal site with an elevated rate of bone turnover.
      However, conventional planar bone scintigraphy was reported to be less sensitive than MRI in
      detecting spinal metastases (3-7).

      18F ion is a positron emitting bone radiopharmaceuticals. The skeletal uptake of 18F relies
      on the exchange of hydroxyl ions in the hydroxyapatit crystal which is an indicator of bone
      metabolic activity (8). It has good soft tissue clearance and high affinity of to the bone
      matrix. It is able to perform a highly sensitive whole-body screening for bone metastases
      using a high resolution PET scanner.

      To the best of our knowledge, there are only limited studies evaluating the clinical
      utilization of 18F-NaF PET for detection of bone metastases (10-12). Therefore, we would like
      to conduct a prospective study to evaluate the accuracy and clinical value of 18F PET in
      staging bone metastases by

        1. Comparing the sensitivity of 18F-NaF PET with that of 99mTc-MDP scintigraphy;

        2. Determining the clinical impact of PET results on subsequent patient management.

      99mTc-MDP scintigraphy and 18F PET will be performed in 2 weeks for all patients.
      Interpretation of 99mTc-MDP scintigraphy and 18F PET will be performed following the criteria
      described by Crasnow et all (13). The accuracy of 99mTc-MDP scintigraphy and 18F PET
      detection of bone metastases for each patient will be determined by the histopathological
      results, MRI results, or other clinical evidences afterward.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>metastatic bone lesion for patients with cancer</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        metastatic bone lesion for patients with cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathology proofed lung cancer and are referred to perform whole-body bone
             scintigraphies for staging metastatic bone diseases

        Exclusion Criteria:

          -  patients whose age are below 18

          -  pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruoh-Fang Yen, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruoh-Fang Yen, M.D.,Ph.D.</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>5581</phone_ext>
    <email>rfyen@ha.mc.ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruoh-Fang Yen, M.D., Ph.D.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>5581</phone_ext>
      <email>rfyen@ha.mc.ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Ruoh-Fang Yen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Tritz DB, Doll DC, Ringenberg QS, Anderson S, Madsen R, Perry MC, Yarbro JW. Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables. Cancer. 1989 Feb 15;63(4):763-6.</citation>
    <PMID>2536586</PMID>
  </reference>
  <reference>
    <citation>Bezwoda WR, Lewis D, Livini N. Bone marrow involvement in anaplastic small cell lung cancer. Diagnosis, hematologic features, and prognostic implications. Cancer. 1986 Oct 15;58(8):1762-5.</citation>
    <PMID>3019512</PMID>
  </reference>
  <reference>
    <citation>Avrahami E, Tadmor R, Dally O, Hadar H. Early MR demonstration of spinal metastases in patients with normal radiographs and CT and radionuclide bone scans. J Comput Assist Tomogr. 1989 Jul-Aug;13(4):598-602.</citation>
    <PMID>2745777</PMID>
  </reference>
  <reference>
    <citation>Brown B, Laorr A, Greenspan A, Stadalnik R. Negative bone scintigraphy with diffuse osteoblastic breast carcinoma metastases. Clin Nucl Med. 1994 Mar;19(3):194-6.</citation>
    <PMID>8033466</PMID>
  </reference>
  <reference>
    <citation>Thrupkaew AK, Henkin RE, Quinn JL 3rd. False negative bone scans in disseminated metastatic disease. Radiology. 1974 Nov;113(2):383-6.</citation>
    <PMID>4419062</PMID>
  </reference>
  <reference>
    <citation>Haubold-Reuter BG, Duewell S, Schilcher BR, Marincek B, von Schulthess GK. The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study. Eur J Nucl Med. 1993 Nov;20(11):1063-9.</citation>
    <PMID>8287874</PMID>
  </reference>
  <reference>
    <citation>Frank JA, Ling A, Patronas NJ, Carrasquillo JA, Horvath K, Hickey AM, Dwyer AJ. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol. 1990 Nov;155(5):1043-8.</citation>
    <PMID>2120933</PMID>
  </reference>
  <reference>
    <citation>Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, Satyamurthy N, Barrio JR, Phelps ME. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992 May;33(5):633-42.</citation>
    <PMID>1569473</PMID>
  </reference>
  <reference>
    <citation>Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, Messer P, Nüssle K, Elsner K, Glatting G, Träger H, Neumaier B, Diederichs C, Reske SN. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999 Aug;17(8):2381-9.</citation>
    <PMID>10561300</PMID>
  </reference>
  <reference>
    <citation>Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Träger H, Nüssle K, Reske SN. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999 Oct;40(10):1623-9.</citation>
    <PMID>10520701</PMID>
  </reference>
  <reference>
    <citation>Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, Dziuk K, Gabelmann A, Reske SN, Hetzel M. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001 Dec;42(12):1800-4.</citation>
    <PMID>11752076</PMID>
  </reference>
  <reference>
    <citation>Hetzel M, Arslandemir C, König HH, Buck AK, Nüssle K, Glatting G, Gabelmann A, Hetzel J, Hombach V, Schirrmeister H. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003 Dec;18(12):2206-14.</citation>
    <PMID>14672356</PMID>
  </reference>
  <reference>
    <citation>Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T, Isitman AT. Diagnostic bone scanning in oncology. Semin Nucl Med. 1997 Apr;27(2):107-41. Review.</citation>
    <PMID>9144855</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>August 13, 2009</last_update_submitted>
  <last_update_submitted_qc>August 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Yen RF</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>bone scan</keyword>
  <keyword>NaF bone PET</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

